Neumora Therapeutics Inc. Common Stock (NMRA) Stock Forecast
Show ratings and price targets of :
Alert
Its only available to paid users.
USD 23.75
(+159.56%)
Based on the Neumora Therapeutics Inc. Common Stock stock forecast from 3 analysts, the average analyst target price for Neumora Therapeutics Inc. Common Stock is USD 23.75 over the next 12 months. Neumora Therapeutics Inc. Common Stock’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Neumora Therapeutics Inc. Common Stock is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Neumora Therapeutics Inc. Common Stock’s stock price was USD 9.15. Neumora Therapeutics Inc. Common Stock’s stock price has changed by -10.12% over the past week, -33.45% over the past month and 0% over the last year.
No recent analyst target price found for Neumora Therapeutics Inc. Common Stock
No recent average analyst rating found for Neumora Therapeutics Inc. Common Stock
Company Overview Neumora Therapeutics Inc. Common Stock
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts. Read Less
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid r...Read More
Frequently Asked Questions About Neumora Therapeutics Inc. Common Stock (NMRA) Stock
Based on ratings from 3 analysts Neumora Therapeutics Inc. Common Stock's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on NMRA's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for NMRA is USD 23.75 over the next 12 months. The maximum analyst target price is USD 31 while the minimum anlayst target price is USD 13.
Unfortunately we do not have enough data on NMRA's stock to indicate if its overvalued.
The last closing price of NMRA's stock was USD 9.15.
The most recent market capitalization for NMRA is USD 2.35B.
Based on targets from 3 analysts, the average taret price for NMRA is projected at USD 23.75 over the next 12 months.
This means that NMRA's stock price may go up by +159.56% over the next 12 months.
We can't find any ETFs which contains Neumora Therapeutics Inc. Common Stock's stock.
As per our most recent records Neumora Therapeutics Inc. Common Stock has 124 Employees.
Neumora Therapeutics Inc. Common Stock's registered address is 490 Arsenal Way, Watertown, MA, United States, 02472.
You can get more information about it from Neumora Therapeutics Inc. Common Stock's website at https://www.neumoratx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NMRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
